Juvenile idiopathic arthritis and risk of cancer: A nationwide cohort study

Arthritis Care and Research

Volumn 62, Issue 12, 2010, Pages 3776-3782

  Simard, J F ^a,b   Neovius, M ^a   Hagelberg, S ^b   Askling, J ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; CANCER PATIENT; CANCER RISK; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENETIC LINKAGE; HOSPITAL DISCHARGE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; POISSON DISTRIBUTION; PRIMARY TUMOR; SENSITIVITY ANALYSIS; ACUTE LYMPHOCYTIC LEUKEMIA; BIOLOGICAL THERAPY; CANCER INCIDENCE; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; HODGKIN DISEASE; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; POPULATION; PRIORITY JOURNAL; RISK FACTOR; STATISTICAL ANALYSIS; VITAL SIGN;

INFLIXIMAB;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, JUVENILE RHEUMATOID; BIOLOGICAL PRODUCTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NEOPLASMS; REGISTRIES; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SWEDEN; YOUNG ADULT;

EID: 78649648584     PISSN: 21514658     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.27741     Document Type: Article

References (16)

1. US Food and Drug Administration MedWatch. Information for healthcare professionals: tumor necrosis factor (TNF) blockers. URL:.
2. US Food and Drug Administration MedWatch. Questions and answers: TNF blockers. URL:.
3. Askling J,. Malignancy and rheumatoid arthritis. Curr Rheumatol Rep 2007; 9: 421-6.
4. Askling J, Bongartz T,. Malignancy and biologic therapy in rheumatoid arthritis. Curr Opin Rheumatol 2008; 20: 334-9.
5. In-patient diseases in Sweden 1987-2003. In: Socialstyrelsen. Stockholm: Welfare SNBoHa; 2005.
6. Nilsson AC, Spetz CL, Carsjo K, Nightingale R, Smedby B,. [ Reliability of the hospital registry: the diagnostic data are better than their reputation ]. Lakartidningen 1994; 91: 598, 603- 5.
7. Causes of death 2007. In: The National Board of Health and Welfare, Centre for Epidemiology. Stockholm: Welfare SNBoHa; 2009.
8. Neovius M, Sundstrom A, Simard JF, Wettermark B, Cars T, Feltelius N, et al. Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009. Scand J Rheumatol 2010. In press.
9. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006; 65: 707-12.
10. Bernatsky S, Rosenberg A, Oen KG, Ramsey-Goldman R, St. Pierre Y, Turnbull E, et al. Malignancy in juvenile idiopathic arthritis [abstract]. Arthritis Rheum 2009; 60 Suppl: S91-2.
11. Harrison M, Nordstrom B, Gu Y, Mercaldi C, Aquino P, Mines D,. Risk of malignancy in biologics-naive juvenile arthritis patients [abstract]. Ann Rheum Dis 2010; 69 Suppl 3: 631.
12. Thomas E, Brewster DH, Black RJ, Macfarlane GJ,. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000; 88: 497-502.
13. Manners PJ, Bower C,. Worldwide prevalence of juvenile arthritis: why does it vary so much? J Rheumatol 2002; 29: 1520-30.
14. Gare BA, Fasth A,. Epidemiology of juvenile chronic arthritis in southwestern Sweden: a 5-year prospective population study. Pediatrics 1992; 90: 950-8.
15. Hjalgrim H, Askling J, Rostgaard K, Hamilton-Dutoit S, Frisch M, Zhang JS, et al. Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med 2003; 349: 1324-32.
16. Harrison M, Cummins C, Horneff G, Southwood T, Mines D,. Cancer risk in juvenile arthritis patients exposed to etanercept: results from three observational cohorts [abstract]. Ann Rheum Dis 2010; 69 Suppl 3: 147.